SUPPLEMENTARY TABLES

Table S1A. Response rates regimens for warm AIHA in CLL

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year\* | Therapy | *n* | Response criteria | ORR (%) | CR or EHR (%) | PR (%) | NR (%) |
| Mauro, 2000 | Prednisone 1-2 mg/kg/day, chlorambucil 10 mg/ m2/ day 6 days | 50 | Hemoglobin, DAT | 84 | 70 | 14 | 16 |
| Kyasa, 2003 | Prednisone 1 mg/kg/ day | 6 | Hemoglobin, hemolysis | 83 | 83 | 0 | 17 |
| Meyer, 1997 | Dexamethasone 40 mg/day 4 days; cycle every 4 weeks | 7 | Hemoglobin, hemolysis, DAT | 100 | 14 | 86 | 0 |
| Besa, 1984 | IVIG 0.3-0.4 g/kg 5 days  | 3 | Hematocrit, indirect bilirubin | 100 | 0 | 100 | 0 |
| Besa, 1988 | IVIG 0.4 g/kg 5 days  | 5 | Hematocrit | 100 | 0 | 100 | 0 |
| Majer, 1988 | IVIG 0.5 g/kg 5 days | 2 | Hemoglobin  | 50 | 0 | 50 | 50 |
| Cortes, 2001 | Cyclosporine A 300 mg/day | 16 | Thiruvengadam criteria | 68 | 56 | 12 | 31 |
| Zaja, 2003 | Rituximab 375 mg/m2/week 4 weeks | 4 | Hemoglobin, DAT, hemolysis, leukocytes | 25 | 25 | 0 | 75 |
| Narat, 2005 | Rituximab 375 mg/m2/week 4 weeks | 4 | Hemoglobin, hemolysis | 100 | 25 | 75 | 0 |
| D’Arena, 2006 | Rituximab 375 mg/m2/week 4 weeks | 14 | Hemoglobin, transfusion dependency, hemolysis | 71 | 21 | 50 | 29 |
| Gupta, 2002 | Rituximab 375 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 2, dexamethasone 12 mg days 2, 3-7; Cycle every 4 weeks  | 8 | Hemoglobin, DAT | 100 | 13 | 87 | 0 |
| Kaufman, 2009 | Rituximab 375 mg/m2 on day 1, cyclophosphamide 750-1000 mg/m2 on day 2, dexamethasone 12 mg days 1-7; Cycle every 3 weeks | 20 | Hemoglobin  | 100 | - | - | 0 |
| Michallet, 2011 | Rituximab 375 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, dexamethasone 12 mg days 1-7; Cycle every 4 weeks | 26 | Hemoglobin | 89.5 | 83 | 6.5 | 10.5 |
| Bowen, 2010 | Rituximab 375 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, vincristine 1.4 mg/m2 on day 1, prednisone 40 mg/m2 days 1-5; cycle every 3 weeks | 17 | Hemoglobin, hemolysis | 100 | - | - | 0 |
| Quinquenel, 2015 | Bendamustine 70-100 mg/m2 days 1-2, rituximab 375-500 mg/m2 on day 1; Cycle every 4 weeks | 26 | Hemoglobin, hemolysis | 81 | 31 | 50 | 19 |
| Vitale, 2016 | Ibrutinib 420 mg/day | 8 | Hemoglobin, hemolysis, DAT | 37.5 | - | - | 62.5 |
| Cusack, 1997 | Splenectomy | 29 | Thiruvengadam criteria | - | 69 | - | - |
| Hill, 2004 | Splenectomy | 9 | Hemoglobin, transfusion dependency | 78 | 78 | 0 | 22 |

\* ORR: overall response rate; CR: complete response; EHR: excellent hematological response; PR: partial response; NR: non-response; DAT: direct antiglobulin test.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year\* | Therapy | *n* | Response criteria | ORR (%) | CR (%) | PR (%) | NR (%) |
| Berentsen, 2006 | Rituximab 375 mg/m2/ week 4 weeks | 52 | Hemoglobin, hemolysis, CAD symptoms, serum IgM | 58 | 5 | 53 | 42 |
| Berentsen, 2010 | Rituximab 375 mg/m2/ week 4 weeks, fludarabine 40 mg/m2 | 29 | Hemoglobin, hemolysis, CAD symptoms, serum IgM | 76 | 21 | 55 | 24 |
| Berentsen, 2017 | Bendamustine 90 mg/m2 days 1-2, rituximab 375 mg/m2/ week; 4 cycles | 45 | Hemoglobin, hemolysis, CAD symptoms, serum IgM | 71 | 40 | 31 | 29 |

Table S1B. Response rates regimens for primary cold AIHA

\* ORR: overall response rate; CR: complete response; PR: partial response; NR: non-response; DAT: direct antiglobulin test.

Table S2. Response rates regimens for ITP in CLL

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year\* | Therapy | *n* | Response criteria | ORR (%) | CR or EHR (%) | PR (%) | NR (%) |
| Kyasa, 2003 | Prednisone 1 mg/ kg/day | 2 | Platelet count | 100 | 50 | 50 | 0 |
| Wei, 2016 | Dexamethasone 40 mg/day 4 days; 1-2 times | 95 | Platelet count, bleeding | 82.1 | 50.5 | 31.6 | 17.9 |
| Besa, 1984 | IVIG 0.3-0.4 g/kg 5 days & maintenance | 1 | Platelet count | 100 | 0 | 100 | 0 |
| Cortes, 2001 | Cyclosporin A 300 mg/day | 29 | Thiruvengadam criteria | 65 | 41 | 24 | 34 |
| Hegde, 2002 | Rituximab 375 mg/m2/week 4 weeks | 3 | Platelet count, bleeding | 100 | 67 | 33 | 0 |
| D’Arena, 2010 | Rituximab 375 mg/m2/week 4 weeks | 21 | Platelet count, bleeding | 86 | 57 | 29 | 14 |
| Michallet, 2011 | Rituximab 375 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, dexamethasone 12 mg days 1-7; Cycle every 4 weeks | 9 | Platelet count | 89.5 | 83 | 6.5 | 10.5 |
| Bowen, 2010 | Rituximab 375 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, vincristine 1.4 mg/m2 on day 1, prednisone 40 mg/m2 days 1-5; cycle every 3 weeks | 8 | Platelet count | 87.5 | - | - | 12.5 |
| Keating, 2013 | Eltrombopag 75-300 mg/day; dose adjustment every 2 weeks | 10 | Platelet count | 80 | 70 | 10 | 20 |
| Gudbrands-dottir, 2012 | Romiplostim, eltrombopag; dose not reported | 3 | Platelet count | 33 | - | - | 67 |
| Sinisalo, 2011 | Romiplostim, eltrombopag; dose not reported | 2 | Platelet count | 100 | - | - | 0 |
| Koehrer, 2010 | Eltrombopag 50 mg/day | 3 | Platelet count | 67 | - | - | 33 |
| Cusack, 1997 | Splenectomy | 18 | Thiruvengadam criteria | - | 61 | - | - |

\* ORR: overall response rate; CR: complete response; EHR: excellent hematological response; PR: partial response; NR: non-response.

Table S3. Response rates regimens for PRCA in CLL

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year\* | Therapy | *n* | Response criteria | ORR (%) | CR (%) | PR (%) | NR (%) |
| Kyasa, 2003 | Prednisone 1 mg/ kg/day | 1 | Hemoglobin, reticulocytes, bone marrow biopsy | 100 | 100 | 0 | 0 |
|  |  |  |  |  |  |  |  |
| Chikkappa, 1992 | Prednisone, cyclosporine A | 7 | Hemoglobin | 86 | - | - | 14 |
| D’Arena, 2009 | Rituximab 375 mg/m2/week 4 weeks | 4 | Hemoglobin, transfusion dependency | 100 | 75 | 25 | 0 |
| Ghazal, 2002 | Rituximab 375 mg/m2/week 8 weeks | 2 | Hemoglobin, reticulocytes, bone marrow biopsy  | 100 | - | - | 0 |
| Michallet, 2011 | Rituximab 375 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, dexamethasone 12 mg days 1-7; Cycle every 4 weeks | 5 | Hemoglobin  | 89.5 | 83 | 6.5 | 10.5 |
| Bowen, 2010 | Rituximab 375 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, vincristine 1.4 mg/m2 on day 1, prednisone 40 mg/m2 days 1-5; cycle every 3 weeks | 2 | Hemoglobin, reticulocytes | 100 | - | - | 0 |

\* ORR: overall response rate; CR: complete response; PR: partial response; NR: non-response.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Author, year\* | Therapy | *n* | Response criteria | ORR (%) | CR (%) | PR (%) | NR (%) |
| Euler, 1997 | G-CSF 48 million units/day 6 days | 9 | PMN counts | 100 | - | - | 0 |
| Costello, 2010Chakupurakal, 2007 | Rituximab 375 mg/m2/week 4 weeks, cyclosporine A 50 mg days 1 & 2, G-CSF 263 μg | 2 | PMN counts | 100 | - | - | 0 |

Table S4. Response rates regimens for AIN

\* ORR: overall response rate; CR: complete response; PR: partial response; NR: non-response.